Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments

References

• Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–1342.
   PubMed Web of Science ®Google Scholar
• de Martel C, Maucort-Boulch D, Plummer M, et al. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62(4):1190–1200.
   PubMed Web of Science ®Google Scholar
• Chen CH, Yang PM, Huang GT, et al. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc. 2007;106(2):148–155.
   PubMed Web of Science ®Google Scholar
• Yu ML, Yeh ML, Tsai PC, et al. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan. Medicine (Baltimore). 2015;94(13):e690.
   PubMed Web of Science ®Google Scholar
• Cozzolongo R, Osella AR, Elba S, et al. Epidemiology of HCV infection in the general population: a survey in a southern Italian town. Am J Gastroenterol. 2009;104(11):2740–2746.
   PubMed Web of Science ®Google Scholar
• Tanaka J, Kumagai J, Katayama K, et al. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology. 2004;47(1):32–40.
   PubMed Web of Science ®Google Scholar
• Dominguez A, Bruguera M, Vidal J, et al. Community-based seroepidemiological survey of HCV infection in Catalonia, Spain. J Med Virol. 2001;65(4):688–693.
   PubMed Web of Science ®Google Scholar
• Meffre C, Le Strat Y, Delarocque-Astagneau E, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol. 2010;82(4):546–555.
   PubMed Web of Science ®Google Scholar
• Vespasiani-Gentilucci U, Galati G, Gallo P, et al. Hepatitis C treatment in the elderly: new possibilities and controversies towards interferon-free regimens. World J Gastroenterol. 2015;21(24):7412–7426.
   PubMed Web of Science ®Google Scholar
• Smith BD, Morgan RL, Beckett GA, et al. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012;157(11):817–822.
   PubMed Web of Science ®Google Scholar
• Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–714.
   PubMed Web of Science ®Google Scholar
• Balogun MA, Ramsay ME, Hesketh LM, et al. The prevalence of hepatitis C in England and Wales. J Infect. 2002;45(4):219–226.
   PubMed Web of Science ®Google Scholar
• Poynard T, Yuen MF, Ratziu V, et al. Viral hepatitis C. Lancet. 2003;362(9401):2095–2100.
   PubMed Web of Science ®Google Scholar
• Pradat P, Voirin N, Tillmann HL, et al. Progression to cirrhosis in hepatitis C patients: an age-dependent process. Liver Int. 2007;27(3):335–339.
   PubMed Web of Science ®Google Scholar
• Minola E, Prati D, Suter F, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood. 2002;99(12):4588–4591.
   PubMed Web of Science ®Google Scholar
• Ryder SD, Irving WL, Jones DA, et al. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004;53(3):451–455.
   PubMed Web of Science ®Google Scholar
• Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol. 2006;101(6):1260–1267.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Messinger D, Popescu M, et al. Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat. 2009;16(10):724–731.
   PubMed Web of Science ®Google Scholar
• Tong MJ, el-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332(22):1463–1466.
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346–355.
   PubMed Web of Science ®Google Scholar
• Iwasaki Y, Takaguchi K, Ikeda H, et al. Risk factors for hepatocellular carcinoma in hepatitis C patients with sustained virologic response to interferon therapy. Liver Int. 2004;24(6):603–610.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Fujiyama S, Tanaka M, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol. 2005;40(2):148–156.
   PubMed Web of Science ®Google Scholar
• Tokita H, Fukui H, Tanaka A, et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol. 2005;20(5):752–758.
   PubMed Web of Science ®Google Scholar
• Huang CF, Yeh ML, Huang CY, et al. Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy. Medicine (Baltimore). 2016;95(27):e4157.
   PubMed Web of Science ®Google Scholar
• Huang CF, Yeh ML, Huang CI, et al. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. Oncotarget. 2017;8(27):43925–43933.
   PubMed Web of Science ®Google Scholar
• Huang CF, Yeh ML, Tsai PC, et al. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. J Hepatol. 2014;61(1):67–74.
   PubMed Web of Science ®Google Scholar
• Huang CF, Dai CY, Yeh ML, et al. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. J Hepatol. 2015;62(3):512–518.
   PubMed Web of Science ®Google Scholar
• Yu ML, Huang CF, Yeh ML, et al. Time-degenerative factors and the risk of hepatocellular carcinoma after antiviral therapy among hepatitis C virus patients: a model for prioritization of treatment. Clin Cancer Res. 2017;23(7):1690–1697.
   PubMed Web of Science ®Google Scholar
• Collins BH, Holzknecht ZE, Lynn KA, et al. Association of age-dependent liver injury and fibrosis with immune cell populations. Liver Int. 2013;33(8):1175–1186.
   PubMed Web of Science ®Google Scholar
• Vermehren J, Peiffer KH, Welsch C, et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2016;44(8):856–865.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Lin MY, Yang YH, et al. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis. 2010;56(1):23–31.
   PubMed Web of Science ®Google Scholar
• Liao CC, Su TC, Sung FC, et al. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PLoS One. 2012;7(2):e31527.
   PubMed Web of Science ®Google Scholar
• Roeder C, Jordan S, Schulze Zur Wiesch J, et al. Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. World J Gastroenterol. 2014;20(31):10984–10993.
   PubMed Web of Science ®Google Scholar
• Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007;56(4):553–559.
   PubMed Web of Science ®Google Scholar
• Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008;47(6):1884–1893.
   PubMed Web of Science ®Google Scholar
• Huang CF, Chuang WL, Yu ML. Chronic hepatitis C infection in the elderly. Kaohsiung J Med Sci. 2011;27(12):533–537.
   PubMed Web of Science ®Google Scholar
• Huang CF, Yang JF, Dai CY, et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis. 2010;201(5):751–759.
   PubMed Web of Science ®Google Scholar
• Yu ML. Hepatitis C Treatment From “Response-guided” to “Resource-guided” therapy in the transition era from IFN-containing to IFN-free regimens. J Gastroenterol Hepatol. 2017;32(8):1436–1442.
   PubMed Web of Science ®Google Scholar
• Tsai P-C, Liu T-W, Tsai Y-S, et al. Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database. Medicine (Baltimore). 2017;96(22):e6984.
   PubMed Web of Science ®Google Scholar
• Furusyo N, Ogawa E, Nakamuta M, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol. 2013;59(2):205–212.
   PubMed Web of Science ®Google Scholar
• Takita M, Hagiwara S, Kudo M, et al. Efficacy and safety of telaprevir-based antiviral treatment for elderly patients with hepatitis C virus. Oncology. 2014;87(Suppl 1):110–117.
   PubMedGoogle Scholar
• Yamagiwa S, Ishikawa T, Waguri N, et al. Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C. World J Hepatol. 2017;9(5):252–262.
   PubMed Web of Science ®Google Scholar
• Colombo M, Strasser S, Moreno C, et al. Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program. J Hepatol. 2014;61(5):976–983.
   PubMed Web of Science ®Google Scholar
• Fujino H, Imamura M, Nagaoki Y, et al. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. J Gastroenterol. 2014;49(12):1548–1556.
   PubMed Web of Science ®Google Scholar
• Yang CC, Tsai WL, Su WW, et al. Rapid prediction of treatment futility of boceprevir with peginterferon-ribavirin for Taiwanese treatment experienced hepatitis C virus genotype 1-infected patients. PLoS One. 2015;10(9):e0137852.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–1887.
   PubMed Web of Science ®Google Scholar
• Gordon SC, Muir AJ, Lim JK, et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol. 2015;62(2):286–293.
   PubMed Web of Science ®Google Scholar
• Aronsohn A, Stainbrook T, Mohanty S, et al. Impact of age on safety and treatment response in patients with hepatitis C treated with boceprevir or telaprevir. Hepatology. 2013;58(Suppl 1):218A.
   PubMedGoogle Scholar
• Saab S, Park SH, Mizokami M, et al. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology. 2016;63(4):1112–1119.
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Foster G, Shiffman M, et al. Safety and efficacy of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C in patients aged 65 years or older: a retrospective analysis of phase 3 studies. Amsterdam, EASL 2017 Poster. April, 2017: SAT-227.
   Google Scholar
• Ogawa E, Furusyo N, Yamashita N, et al. Effectiveness and safety of daclatasvir plus asunaprevir for HCV genotype 1b patients aged 75 and over with or without cirrhosis. Hepatol Res. 2017;47(3):E120–E131.
   PubMed Web of Science ®Google Scholar
• Toyoda H, Kumada T, Tada T, et al. Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B. J Hepatol. 2017;66(3):521–527.
   PubMed Web of Science ®Google Scholar
• Ogawa E, Furusyo N, Nomura H, et al. Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. Antiviral Res. 2016;136:37–44.
   PubMed Web of Science ®Google Scholar
• Conti F, Brillanti S, Buonfiglioli F, et al. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older. J Viral Hepat. 2016;24(6):454–463.
   Web of Science ®Google Scholar
• Pellicelli AM, Pace Palitti V, Vignally P, et al. Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: a real-life study. Liver Int. 2016;37(5):653–661.
   PubMed Web of Science ®Google Scholar
• Su F, Beste LA, Green PK, et al. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17487 patients. Eur J Gastroenterol Hepatol. 2017;29(6):686–693.
   PubMed Web of Science ®Google Scholar
• Backus LI, Belperio PS, Shahoumian TA, et al. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology. 2016;64(2):405–414.
   PubMed Web of Science ®Google Scholar
• Backus LI, Belperio PS, Shahoumian TA, et al. Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients. Antivir Ther. In press. PMID 27934775
   Google Scholar
• Backus LI, Belperio PS, Shahoumian TA, et al. Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther. 2016;44(4):400–410.
   PubMed Web of Science ®Google Scholar
• Flisiak R, Pogorzelska J, Flisiak-Jackiewicz M. Hepatitis C: efficacy and safety in real life. Liver Int. 2017;37(Suppl 1):26–32.
   PubMedGoogle Scholar
• Ogawa E, Furusyo N, Naoki Yamashita AK, et al. Effectiveness and safety of daclatasvir plus asunaprevir for HCV genotype 1b patients aged 75 and over with or without cirrhosis. Hepatol Res. 2016;47(3):E120–131.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Lin MY, Chang JS, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One. 2014;9(6):e100790.
   PubMed Web of Science ®Google Scholar
• Li T, Qu Y, Guo Y, et al. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. Liver Int. 2016;37(7):974–981.
   Web of Science ®Google Scholar
• Welzel TM, Hinrichsen H, Sarrazin C, et al. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. J Viral Hepat. 2017;24(10):840–849.
   PubMed Web of Science ®Google Scholar
• Welzel TM, Nelson DR, Morelli G, et al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut. 2016;66(10):1844–1852.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology. 2016;150(2):419–429.
   PubMed Web of Science ®Google Scholar
• Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016;65(11):1861–1870.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Zeuzem S, Di Bisceglie AM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131–1140.e1135.
   PubMed Web of Science ®Google Scholar
• Tapper EB, Bacon BR, Curry MP, et al. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepat. 2017;24(1):22–27.
   PubMed Web of Science ®Google Scholar
• Kondili LA, Gaeta GB, Ieluzzi D, et al. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One. 2017;12(2):e0172159.
   PubMed Web of Science ®Google Scholar
• Sicras. European Association for the Study of the Liver (EASL) 2016. Barcelona, Poster SAT-116. April, 2016.
   Google Scholar
• Younossi Z, Park H, Henry L, et al. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016;150(7):1599–1608.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Comarmond C, Domont F, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3(1):3–14.
   PubMed Web of Science ®Google Scholar
• Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–954.
   PubMed Web of Science ®Google Scholar
• Ming-Lung Y, Huang C-F. Editorial: the unexpected high risk of occurrence or recurrence of hepatocellular carcinoma after successful antiviral therapy with interferon-free direct-acting antivirals. Transl Cancer Res. 2016;5(Suppl 6):S1111–S1115.
   Google Scholar
• Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. In press. PMID 28802876
   Web of Science ®Google Scholar
• Poynard T, Moussalli J, Munteanu M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013;59(4):675–683.
   PubMed Web of Science ®Google Scholar
• Nagaoki Y, Aikata H, Nakano N, et al. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: a large-scale, long-term cohort study. J Gastroenterol Hepatol. 2016;31(5):1009–1015.
   PubMed Web of Science ®Google Scholar